Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BMS-986165 in moderate to severe psoriasis
NCT02931838Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Started Nov 2016; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02931838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931838.